Provided by Tiger Trade Technology Pte. Ltd.

Allogene Therapeutics Inc.

2.28
+0.01000.44%
Post-market: 2.26-0.0200-0.88%19:49 EDT
Volume:4.48M
Turnover:10.30M
Market Cap:786.60M
PE:-2.64
High:2.36
Open:2.29
Low:2.25
Close:2.27
52wk High:4.46
52wk Low:0.8621
Shares:345.00M
Float Shares:275.00M
Volume Ratio:0.72
T/O Rate:1.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8652
EPS(LYR):-0.8652
ROE:-53.42%
ROA:-26.82%
PB:2.69
PE(LYR):-2.64

Loading ...

Allogene Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview

Reuters
·
May 08

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

THOMSON REUTERS
·
May 06

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 06

Allogene wins South Korea, Australia regulatory clearance to expand ALPHA3 trial

Reuters
·
Apr 21

Allogene Therapeutics Expands Pivotal Phase 2 Alpha3 Trial to South Korea and Australia

THOMSON REUTERS
·
Apr 21

Allogene Therapeutics Inc - Interim Efs Analysis Anticipated in Mid-2027, Primary Efs Analysis in Mid-2028

THOMSON REUTERS
·
Apr 21

Allogene Therapeutics Inc - Patient Screening and Enrollment Expected to Begin in Q2 2026

THOMSON REUTERS
·
Apr 21

Allogene Therapeutics announces annual shareholder meeting notice

Reuters
·
Apr 21

Allogene Therapeutics to present allogeneic CAR-T data at AACR annual meeting

Reuters
·
Apr 20

Allogene presents preclinical BCMA/CD70 dual CAR-T data for multiple myeloma at AACR

Reuters
·
Apr 20

Press Release: Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock

Dow Jones
·
Apr 17

Allogene Therapeutics Inc : JP Morgan Raises to Neutral From Underweight

THOMSON REUTERS
·
Apr 16

U.S. RESEARCH ROUNDUP-CME Group, M&T Bank, PNC Financial Services

Reuters
·
Apr 16

NASD Most Active Issues

Dow Jones
·
Apr 16

BUZZ-U.S. STOCKS ON THE MOVE-Nike, PNC Financia, OSI Systems

Reuters
·
Apr 16

Unusually active option classes on open April 15th

TIPRANKS
·
Apr 15

Allogene enrolls Phase 1 RESOLUTION trial of ALLO-329 in autoimmune diseases

Reuters
·
Apr 15

Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases

GlobeNewswire
·
Apr 15

BRIEF-Allogene Therapeutics Announces Pricing Of Public Offering Of Common Stock

Reuters
·
Apr 15

Allogene prices 87,500,000-share follow-on offering at $2 per share

Reuters
·
Apr 15